NexMab™ ADC Candidates
Oncology
DiscoveryActive
Key Facts
About Alteogen
Alteogen's mission is to develop innovative biobetter and biosimilar pharmaceuticals through its proprietary technology platforms. The company achieved a watershed financial performance in 2025, with consolidated revenue of KRW 2.159 trillion (approx. $1.6B USD) and net profit of KRW 1.443 trillion, driven by its platform-centric business model of licensing and profit-sharing. Its strategy focuses on expanding its technology moat through R&D and securing global partnerships to commercialize its pipeline, while transitioning to a mature, shareholder-returning entity.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |
| Dual-Targeting CAR-T Programs | Factor Bioscience | Pre-clinical |